Syngene announced its Q2 FY26 results with revenue from operations at ₹911 Cr, a 2% year-over-year increase. The company secured its first global phase III clinical trial from a U.S.-based biotech company and expanded its clinical trials footprint. Syngene also expanded its biologics facility and progressed with its Bayview biologics manufacturing facility. The company’s EcoVadis 2025 score rose to 74/100, placing it in the 91st percentile for sustainability.
Financial Performance
Syngene reported revenue from operations of ₹911 Cr in Q2 FY26, representing a 2% year-over-year growth. The Operating EBITDA margin stood at 22% compared to 27% in Q2 FY25. For H1 FY26, revenue from operations was ₹1,785 Cr, a 6% increase year-over-year, with an Operating EBITDA margin of 23%.
Global Clinical Trial
Syngene secured its first global phase III clinical trial from a U.S.-based biotech company. This trial will involve recruiting patients at clinical sites in both India and the U.S.
Facility Expansions and Progress
The company is expanding its biologics facility in Bengaluru with a GMP bioconjugation suite to provide fully integrated, end-to-end manufacturing of ADCs. Progress at the Bayview biologics manufacturing facility in the U.S. remains on track, with operationalization expected in the second half of the year.
Sustainability Recognition
Syngene’s sustainability assessment earned the highest level ‘Green Certification,’ with a score exceeding 94%. The EcoVadis 2025 score rose to 74/100, placing the company in the 91st percentile worldwide for sustainability practices.
Source: BSE
